Payment overview · 2025
General Payments
$795.30
32 reported records · 9 companies
Healthcare provider profile · identity verified
George Gabriel Toldness, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LAS VEGAS, NV · NPI 1720646045
Verified facts
What the public records show
CMS Open Payments records show George Gabriel Toldness, APRN received $795.30 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $271.72 | 34.2% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $207.10 | 26.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.10 | 11.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.01 | 8.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.69 | 8.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.74 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.08 | 2.4% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.06 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.80 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $795.30 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $207.10 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $201.20 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.98 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.98 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.69 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.58 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.44 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 388 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 296 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 110 |
| Alprazolam | Alprazolam | 280 | 69 |
| Lisinopril | Lisinopril | 275 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 82 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 195 | 38 |
| Losartan Potassium | Losartan Potassium | 187 | 68 |
| Metformin Hcl | Metformin Hcl | 170 | 66 |
| Gabapentin | Gabapentin | 167 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 62 |
| Montelukast Sodium | Montelukast Sodium | 154 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 61 |
| Famotidine | Famotidine | 147 | 62 |
| Omeprazole | Omeprazole | 144 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 59 |
| Mounjaro | Tirzepatide | 133 | 28 |
| Methylprednisolone | Methylprednisolone | 128 | 96 |
| Glimepiride | Glimepiride | 127 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 99 | 81 |
| Tramadol Hcl | Tramadol Hcl | 92 | 37 |
| Finasteride | Finasteride | 85 | 34 |
| Allopurinol | Allopurinol | 84 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 80 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | 15 |
| Lorazepam | Lorazepam | 75 | 18 |
| Irbesartan | Irbesartan | 74 | 30 |
| Trazodone Hcl | Trazodone Hcl | 74 | 27 |
| Alendronate Sodium | Alendronate Sodium | 73 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 27 |
| Eliquis | Apixaban | 71 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 37 |
| Simvastatin | Simvastatin | 69 | 28 |
| Temazepam | Temazepam | 66 | 13 |
| Ezetimibe | Ezetimibe | 65 | 24 |
| Furosemide | Furosemide | 64 | 25 |
| Cefdinir | Cefdinir | 63 | 53 |
| Sulindac | Sulindac | 62 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 48 |
| Potassium Chloride | Potassium Chloride | 57 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 17 |
| Clonazepam | Clonazepam | 53 | 18 |
| Ondansetron Odt | Ondansetron | 52 | 29 |
| Carvedilol | Carvedilol | 50 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 32 |
| Ibuprofen | Ibuprofen | 49 | 27 |
| Clonidine Hcl | Clonidine Hcl | 46 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 18 |
| Spironolactone | Spironolactone | 46 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 20 |
| Sertraline Hcl | Sertraline Hcl | 43 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 17 |
| Jardiance | Empagliflozin | 40 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 19 |
| Meloxicam | Meloxicam | 37 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 16 |
| Naproxen | Naproxen | 36 | 15 |
| Primidone | Primidone | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 25 |
| Nifedipine Er | Nifedipine | 33 | 13 |
| Prednisone | Prednisone | 33 | 21 |
| Diazepam | Diazepam | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 24 |
| Risperidone | Risperidone | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | 12 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 13 |
| Fenofibrate | Fenofibrate | 27 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | 15 |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 18 |
| Clotrimazole | Clotrimazole | 25 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 11 |
| Farxiga | Dapagliflozin Propanediol | 22 | 11 |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 21 | 18 |
| Topiramate | Topiramate | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Baclofen | Baclofen | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 11 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | 11 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $795.30 · 32 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, ImmunoCAP, JARDIANCE, KRYSTEXXA, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error